Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Global X Robotics and Artificial Intelligence ETF (BOTZ) vs Johnson & Johnson (JNJ) Price & Performance

Global X Robotics and Artificial Intelligence ETFTrade
Johnson & JohnsonTrade

Price performance (Past 24H)

Key statistics

Global X Robotics and Artificial Intelligence ETF vs Johnson & Johnson — how do they compare? Global X Robotics and Artificial Intelligence ETF trades at $37.85, while Johnson & Johnson trades at $261.07 (market cap $626.09B). The key difference: Johnson & Johnson pays a 2.06% dividend while Global X Robotics and Artificial Intelligence ETF pays none, and Johnson & Johnson is trading nearer its 52-week high, Global X Robotics and Artificial Intelligence ETF nearer its low. Which is the better fit depends on your goals.

BOTZJNJ
52-Week High
$41.63$267.24
52-Week Low
$31.99$172.78
Market Cap
$626.09B
Volume
6,156,228
Sector
Health
Enterprise Value
$654.37B
Dividend Yield
2.06%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Global X Robotics and Artificial Intelligence ETF

BOTZ trades at $37.92, up 1.34% with a bullish technical signal supported by moving averages. The robotics and AI ETF shows strong momentum with key resistance at $38. Recent articles highlight BOTZ as the largest pure-play robotics fund, positioned to benefit from the shift from digital to physical AI applications. The fund offers exposure to global robotics leaders with a lower expense ratio than peers.

Outlook remains positive as robotics adoption accelerates globally, though overbought RSI signals near-term caution. Investment opportunity lies in AI's expansion into physical automation, while risks include sector concentration and valuation pressures in tech. The fund's global diversification provides exposure to non-US AI innovation.

Johnson & Johnson

Johnson & Johnson (JNJ) trades at $261.26, down 0.21% on the day, near its 52-week high. The stock shows a bullish technical trend with strong moving averages and recent earnings beats. Revenue grew to $94.19B in 2025, with a net income margin of 21.48%, though cash flow turned negative due to heavy investing. The company maintains a robust dividend history, with consistent payouts and a 64-year growth streak.

Outlook remains positive with a consensus price target of $284.50, offering ~9% upside. Risks include legal headwinds and patent expirations, but analyst sentiment is bullish (52.5% buy ratings). JNJ's defensive profile and pipeline strength support long-term growth, though investors should monitor debt levels, which rose to 24.06% of assets in 2025.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Global X Robotics and Artificial Intelligence ETF

The fund invests at least 80% of its total assets in the securities of the underlying index. The underlying index is designed to provide exposure to exchange-listed companies in developed markets that are involved in the development of robotics and/or artificial intelligence. The fund is non-diversified.

Read more on BOTZ

About Johnson & Johnson

Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.

Read more on JNJ